Spoken Alpha
Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals provides in-licensed diagnostic tests for celiac disease, respiratory infections, H. pylori, and hepatocellular carcinoma, with CE mark approval for European markets. The company previously developed rencofilstat, a cyclophilin inhibitor for chronic liver disease, but discontinued that program and sold related assets in 2025.
Hepion Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add CTRVP, reply to your welcome email and we'll prioritize it.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CTRVP.
$ curl https://api.spokenalpha.com/v1/companies/CTRVPFAQ
Spoken Alpha indexes CTRVP's earnings call transcripts at https://spokenalpha.com/companies/CTRVP. Each call links to attributed speakers and parsed analyst Q&A. Hepion Pharmaceuticals, Inc.'s own investor relations page is at https://hepionpharma.com/investors/.
Hepion Pharmaceuticals, Inc. (CTRVP) operates in the Healthcare sector (Biotechnology industry).